BioNTech SE (BNTX) vs Medline Inc. (MDLN)

A side-by-side comparison of BioNTech SE and Medline Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of August 20, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total returnBNTX vs MDLN

growth of $100 · dividends reinvested · last 1y
BNTX +22.6% (+22.6%/yr)MDLN -17.3% (-17.3%/yr)BNTX compounded faster over this window
8090100110120130Start $1002026$123$83
BNTX MDLN

BNTX vs MDLN: by the numbers

  • MDLN is the larger company ($28.67B vs $28.42B market cap).
  • MDLN is profitable (2.31% net margin) while BNTX runs a net loss (-62.98%).

Metrics side by side

Valuation

MetricBNTXMDLN
P/E ratioN/A39.43
Forward P/EN/A22.16
P/S ratio9.250.98
P/B ratio1.412.52
EV / EBITDAN/A14.34
FCF yield2.16%6.94%

Profitability

MetricBNTXMDLN
Gross margin70.98%25.02%
Operating margin-22.63%6.07%
Net margin-62.98%2.31%
ROE-9.62%5.97%
ROIC-10.37%4.05%

Growth (annualized)

MetricBNTXMDLN
Revenue CAGR (5Y)40.61%N/A
Total return CAGR (5Y)-19.15%N/A

Frequently asked

Is BNTX or MDLN more profitable?
MDLN runs the higher net margin — BNTX at -62.98% versus MDLN at 2.31%.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified August 20, 2026.